Pardanani, A <br/><br/>
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.  [electronic resource] 

 -  Leukemia  04 2018 
 - 1035-1038 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2017.330  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Benzamides--therapeutic use<br/>Female<br/>Humans<br/>Janus Kinase 1--antagonists & inhibitors<br/>Janus Kinase 2--antagonists & inhibitors<br/>Male<br/>Middle Aged<br/>Primary Myelofibrosis--drug therapy<br/>Protein Kinase Inhibitors--therapeutic use<br/>Pyrimidines--therapeutic use<br/>Thrombocytosis--drug therapy